What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis.
Ciro CelsaGiacomo Emanuele Maria RizzoGabriele Di MariaMarco EneaMarco VaccaroGabriele RancatorePietro GraceffaGiuseppe FalcoSalvatore PettaGiuseppe CabibboVincenza CalvarusoAntonio CraxìCalogero CammàVito Di MarcoPublished in: Liver international : official journal of the International Association for the Study of the Liver (2024)
Our DCA in HBsAg-negative anti-HBc-positive patients provided evidence that NA prophylaxis is strongly recommended in patients treated with chemotherapy combined with rituximab and could be appropriate in patients with cancer treated with targeted therapies and in patients with immune-mediated diseases. Finally, in patients with cancer treated with monoclonal antibodies or with chemotherapy without rituximab, the net benefit is even lower.